AbbVie (NYSE: ABBV) announced Thursday that it will acquire Immunogen (NASDAQ: IMGN) and its flagship cancer therapy, Elahere, in a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot List Mergers and Acquisitions

Midday movers: Snowflake, Salesforce, and moreNovember 30, 2023 8:12 AM Immunogen (IMGN) call put ratio 22 calls to 1 put into AbbVie (ABBV) to acquire November 30, 2023 7:55 AM AbbVie seeks lift from 'guided missile' cancer drug with $10 billion ImmunoGen dealNovember 30, 2023 7:45 AM Sutro Biopharma (STRO) Trades Higher in Sympathy with Immunogen (IMGN)November 30, 2023 7:45 AM Immunogen (IMGN) to Resume Trading at 8 a.m. Following News of Takeover by AbbVie (ABBV)November 30, 2023 7:41 AM AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $31.26 Per Share, $10.1 BillionNovember 30, 2023 7:31 AM AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor PortfolioNovember 30, 2023 7:30 AM Immunogen (IMGN) Halted, News PendingNovember 30, 2023 7:27 AM Form 144 ImmunoGen, Inc. Filed by: Wingrove TheresaNovember 29, 2023 4:28 PM